# Trelegy Ellipta

NDC: 0173-0887
Generic name: fluticasone furoate, umeclidinium bromide and vilanterol trifenatate
Labeler / Manufacturer: GlaxoSmithKline LLC
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: New Drug Application (innovator)
Dosage form: POWDER
Routes: RESPIRATORY (INHALATION)
Marketing started: 20170918

FDA application: NDA209482

## Active ingredients

- FLUTICASONE FUROATE: 100 ug/1
- UMECLIDINIUM BROMIDE: 62.5 ug/1
- VILANTEROL TRIFENATATE: 25 ug/1

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"0173-0887"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=0173-0887
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b5a81d5a-4648-4c7a-951d-33c014a63c7e